Pyxis Oncology, Inc.
Business
Pyxis Oncology is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) targeting the tumor microenvironment. Its lead candidate, micvotabart pelidotin (MICVO), is a novel ADC binding to extradomain-B fibronectin (EDB+FN) in the tumor extracellular matrix, currently in Phase 1/2 trials for recurrent/metastatic head and neck squamous cell carcinoma as monotherapy and in combination with pembrolizumab. The company also holds paused programs including anti-Siglec-15, anti-CD123 ADC, and CD40 agonist candidates, and operates licensing partnerships generating milestone and royalty revenue from third-party development programs.
Summary from 10-K filed 2026-03-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 14 | 16 | — | — | — | |
| Cost of revenues | 2 | 475,000 | — | — | — | |
| Research and development | 74 | 59 | 50 | 86 | 51 | |
| General and administrative | 22 | 25 | 33 | 37 | 19 | |
| Impairment of in-process research and development intangible asset | 0 | 21 | 0 | — | — | |
| Total costs and operating expenses | 98 | 106 | 82 | — | — | |
| Loss from operations | −84 | −89 | −82 | −123 | −70 | |
| Interest and investment income, net | 4 | 7 | 7 | 3 | — | |
| Sublease income | 3 | 3 | 2 | — | — | |
| Total other income, net | 6 | 10 | 8 | 3 | −6 | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total | −78 | −79 | −74 | — | — | |
| Income tax expense (benefit) | 1 | −2 | — | — | — | |
| Net loss | −80 | −77 | −74 | −121 | −76 | |
| Net loss per common share - basic | −1.28 | −1.32 | −1.85 | −3.65 | −8.95 | |
| Net loss per common share - diluted | −1.28 | −1.32 | −1.85 | −3.65 | −8.95 | |
| Weighted average shares of common stock outstanding - basic | 62 | 58 | 40 | 33 | 8 | |
| Weighted average shares of common stock outstanding - diluted | 62 | 58 | 40 | 33 | 8 | |
| Net unrealized (loss) gain on marketable debt securities | −117,000 | 107,000 | 63,000 | — | — | |
| Other comprehensive (loss) income | −117,000 | 107,000 | 63,000 | — | — | |
| Comprehensive loss | −80 | −77 | −74 | −121 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 15 | 19 | 10 | 179 | — | |
| Marketable debt securities | 51 | 107 | 110 | — | — | |
| Restricted cash | 1 | 1 | 1 | 1 | — | |
| Prepaid expenses and other current assets | 4 | 4 | 4 | 6 | — | |
| Total current assets | 72 | 132 | 125 | 187 | — | |
| Property and equipment, net | 8 | 10 | 12 | 11 | — | |
| Intangible assets, net | 0 | 3 | 24 | — | — | |
| Operating lease right-of-use asset | 11 | 12 | 13 | 14 | 15 | |
| Total assets | 92 | 157 | 174 | 211 | — | |
| Accounts payable | 11 | 5 | 4 | 7 | — | |
| Accrued expenses and other current liabilities | 9 | 11 | 13 | 25 | — | |
| Operating lease liabilities, current portion | 2 | 1 | 1 | — | — | |
| Total current liabilities | 21 | 18 | 26 | 32 | — | |
| Operating lease liabilities, net of current portion | 17 | 19 | 20 | 19 | 15 | |
| Financing lease liabilities, net of current portion | 23,000 | 100,000 | — | — | — | |
| Total liabilities | 38 | 36 | 48 | 51 | — | |
| Commitments and contingencies (Note 19) | — | — | — | — | — | |
| Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding | — | — | — | — | — | |
| Common stock, par value $0.001 per share; 190,000,000 shares authorized; 62,690,229 and 59,967,814 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 63,000 | 60,000 | 45,000 | 34,000 | — | |
| Additional paid-in capital | 496 | 484 | 412 | 373 | — | |
| Accumulated other comprehensive income | 53,000 | 170,000 | 63,000 | — | — | |
| Accumulated deficit | −443 | −364 | −286 | −212 | — | |
| Total stockholders' equity | 53 | 121 | 126 | 161 | — | |
| Total liabilities and stockholders' equity | 92 | 157 | 174 | 211 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −80 | −77 | −74 | −121 | −76 | |
| Depreciation and amortization | 5 | 3 | 2 | 709,000 | 600,000 | |
| Stock-based compensation | 12 | 13 | 17 | 16 | 6 | |
| Non-cash operating lease expense | 824,000 | 700,000 | 660,000 | 1 | 604,000 | |
| Accretion of discount on marketable debt securities | −3 | −6 | −5 | — | — | |
| Prepaid expenses and other current assets | 261,000 | −203,000 | 3 | −3 | −2 | |
| Accounts payable | 6 | 1 | −4 | −8 | 5 | |
| Accrued expenses and other current liabilities | −3 | −2 | −14 | 12 | 5 | |
| Operating lease liabilities | −1 | −1 | 2 | 4 | −615,000 | |
| Deferred revenues | — | −8 | 998,000 | — | — | |
| Deferred tax liabilities | — | −2 | — | — | — | |
| Other | −71,000 | −95,000 | — | — | — | |
| Net cash used in operating activities | −64 | −58 | −71 | −89 | −35 | |
| Redemption of marketable debt securities | 166 | 169 | 92 | — | — | |
| Purchase of marketable debt securities | −107 | −160 | −197 | — | — | |
| Purchase of property and equipment | −9,000 | −237,000 | −7 | −6 | −540,000 | |
| Net cash provided by (used in) investing activities | 59 | 8 | −105 | −6 | −590,000 | |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs | 2,000 | 47 | — | — | — | |
| Proceeds from issuance of common stock pursuant to ATM program, net of offering costs | 0 | 12 | 6 | — | — | |
| Tax withholding payments related to net settlement of restricted common stock | −148,000 | −240,000 | −445,000 | — | — | |
| Proceeds from the exercise of stock options | 632,000 | 296,000 | 120,000 | 183,000 | 167,000 | |
| Proceeds from issuance of common stock under ESPP | 108,000 | 224,000 | 132,000 | — | — | |
| Net cash provided by financing activities | 594,000 | 59 | 6 | 183,000 | 304 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −4 | 10 | −170 | −96 | 268 | |
| Cash paid for interest | 91,000 | 10,000 | 1,000 | — | — | |
| Cash paid for income taxes | 1 | 164,000 | 48,000 | — | — | |
| ROU asset in exchange for financing lease liability | — | 265,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Pyxis Oncology, Inc.'s CIK number?
Pyxis Oncology, Inc.'s SEC CIK number is 0001782223 (1782223). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pyxis Oncology, Inc.'s SEC filings?
All of Pyxis Oncology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Pyxis Oncology, Inc. last report earnings?
Pyxis Oncology, Inc. (PYXS) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222818). This is Pyxis Oncology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Pyxis Oncology, Inc.'s most recent earnings 8-K?
Pyxis Oncology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222818. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Pyxis Oncology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →